Cephalon Growth Strategy Extends To Devices Via $161 Mil. SIRTeX Purchase
This article was originally published in The Gray Sheet
Executive Summary
Biopharmaceutical firm Cephalon is expanding its growth strategy to include medical devices with a $161 mil. cash bid to acquire liver cancer technology manufacturer SIRTeX Medical, announced Feb. 12